



Press Release

For Immediate Release

Dr. Martine George to join Cytomics Pharmaceuticals' Supervisory Board

Orsay (France) – April 30, 2008 - CYTOMICS PHARMACEUTICALS, a privately-held development-stage company with proprietary expertise in the emerging Ubiquitin-Proteasome pathway to develop novel anticancer agents, today announced the appointment of Dr. Martine George, MD., PhD. an industry veteran in clinical oncology as an independent member of its Supervisory Board.

"It is a great honor and a great opportunity for us to welcome Martine to our Board. Her long-standing experience in clinical oncology at the highest level in the international pharmaceutical industry is a unique asset to help shaping the future of the Company. Among many anticancer drugs that Martine has contributed to bringing to the market, she has been a major participant in the development of Velcade™, the first in-class proteasome-inhibitor approved as anticancer agent", **said Thierry Hercend, MD., PhD., Chairman of the Supervisory Board.**

Dr. Martine George, a dual French-American citizen, is currently Senior Vice President, Drug Development and Chief Medical Officer with GPC Biotech based in Germany and United States. Martine is located in Princeton, New Jersey. She is an internationally well-known oncology expert with over fifteen years of experience at major pharmaceutical companies, as well as several years in an academic position at the Institute Gustave Roussy, Villejuif, France. Prior to joining GPC Biotech, Martine was Senior Vice President, Head of Oncology at Johnson & Johnson Pharmaceutical Research and Development. Before that she held a number of executive positions in the areas of clinical and medical affairs, including at Johnson & Johnson, Rhone-Poulenc Rorer (now part of Sanofi-Aventis), Sandoz Pharmaceuticals Corporation (now Novartis) and American Cyanamid.

Dr. Cécile Bougeret, Senior Vice President, Research commented: *"Our Company is currently capitalizing on several novel anticancer chemical entities with distinct biological activity profiles that have emerged from our proprietary platform. The joining of Martine brings the first-class experience that a company at our stage needs to translate its research into the clinical environment. We are fortunate that she has accepted to join our Supervisory Board".*

Dr. Martine George added: *"I am very happy to join the Supervisory Board of Cytomics and help the management team to turn some breakthrough scientific discovery in the field of the ubiquitin-proteasome pathway into potential products for the treatment of cancer. I know by experience that it is an emerging, highly competitive pathway and it is very exciting to try these new approaches for the benefit of patients who suffer from life threatening diseases."*

About CYTOMICS PHARMACEUTICALS

CYTOMICS PHARMACEUTICALS is a biopharmaceutical company pioneering the discovery and development of drugs that control the degradation of proteins, to treat major human diseases such as cancer and fungal infections. The Company was founded in 2000 by Dominique Thomas, PhD, Director of Research at the CNRS Center for Molecular Genetics, and internationally recognized for his work in the field of the Ubiquitin-Proteasome pathway for protein degradation.

The Company has developed an innovative high-throughput screening technology, *UbiScreen*[™], for the discovery of new therapeutic molecules controlling the degradation of target proteins. *CYTOMICS PHARMACEUTICALS* has used this technology to target cancers and fungal infections with compounds at the preclinical stage.

Cytomics Pharmaceuticals (www.cytomics.fr) is based in Orsay (France).

Contacts

CYTOMICS PHARMACEUTICALS

Erwan MARTIN, CFO

Tél. : +33 (0)1 69 18 72 08

E-mail : emartin@cytomics.fr

MILESTONES – Press Relations

Bruno ARABIAN –

Tél. : +33 (0)1 70 08 04 13 / +33 (0)6 87 88 47 26

E-mail : milestones@milestones-fr.com